Literature DB >> 1480677

Altered interleukin-2 production in schizophrenia: association between clinical state and autoantibody production.

R Ganguli1, J S Brar, W Solomon, K N Chengappa, B S Rabin.   

Abstract

Mitogen-stimulated interleukin-2 (IL-2) production was measured in 122 patients who met Research Diagnostic Criteria for schizophrenia and 98 normal control subjects. The presence of autoantibodies against seven common antigens was also determined. There was no relationship between the presence of circulating autoantibodies and IL-2 production in control subjects. In patients, however, autoantibody-positive, acutely ill patients had significantly lower IL-2 production as compared with other patients and control subjects. Never-medicated patients showed the same trends for decreased IL-2 production in association with autoantibodies. These data suggest that decreased IL-2 production is associated with acute illness in schizophrenic patients who produce autoantibodies, a trait known to be associated with increased vulnerability to autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1480677     DOI: 10.1016/0165-1781(92)90046-6

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  8 in total

Review 1.  COX-2 inhibitors as adjunctive therapy in schizophrenia: rationale for use and evidence to date.

Authors:  Michael Riedel; Martin Strassnig; Markus J Schwarz; Norbert Müller
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

2.  IL-2 and IL-4 polymorphisms as candidate genes in schizophrenia.

Authors:  Markus J Schwarz; Holger Krönig; Michael Riedel; Sandra Dehning; Anette Douhet; Ilja Spellmann; Manfred Ackenheil; Hans-Jürgen Möller; Norbert Müller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-08-17       Impact factor: 5.270

3.  Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients.

Authors:  I Wilke; V Arolt; M Rothermundt; C Weitzsch; M Hornberg; H Kirchner
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1996       Impact factor: 5.270

Review 4.  Viruses, schizophrenia, and bipolar disorder.

Authors:  R H Yolken; E F Torrey
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

Review 5.  [Cytokine network in patients with schizophrenia and its significance for the pathophysiology of the illness].

Authors:  A Schuld; D Hinze-Selch; Th Pollmächer
Journal:  Nervenarzt       Date:  2004-03       Impact factor: 1.214

6.  Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression.

Authors:  M Maes; H Y Meltzer; P Buckley; E Bosmans
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1995       Impact factor: 5.270

7.  Cytokines, neurophysiology, neuropsychology, and psychiatric symptoms.

Authors:  Markus J Schwarz
Journal:  Dialogues Clin Neurosci       Date:  2003-06       Impact factor: 5.986

Review 8.  Therapeutic Drug Monitoring of Second- and Third-Generation Antipsychotic Drugs-Influence of Smoking Behavior and Inflammation on Pharmacokinetics.

Authors:  Nicole Moschny; Gudrun Hefner; Renate Grohmann; Gabriel Eckermann; Hannah B Maier; Johanna Seifert; Johannes Heck; Flverly Francis; Stefan Bleich; Sermin Toto; Catharina Meissner
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.